The use of blood samples from donors to develop new cancer therapies
Research type
Research Study
Full title
The use of normal donor blood samples in assays to aid the discovery of new drugs for cancer therapy.
IRAS ID
201569
Contact name
Sarah Holt
Contact email
Sponsor organisation
Cancer Research UK
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
At Cancer Research UK we are dedicated to the discovery of novel agents to be used in the treatment, diagnosis and monitoring of cancer. In order to maximise our approaches to this we have recently established a new laboratory in Cambridge to develop new biologics in an alliance with Medimmune, the biologics division of AstraZeneca.
The aim of this study is to establish and utilise assays to enable us to screen new antibodies (biologics) as part of our discovery and development cascade. A number of the targets we are exploring utilise aspects of the human immune system and in order to recapitulate this in the laboratory it is essential that we access blood from donors. Blood samples will be acquired from a 3rd party (e.g. NHSBT, clinician, commercial supplier). Once in our laboratory samples will be processed to obtain the relevant cells (e.g. T-cells) and then used in our screening assays in order to help us understand the mechanism of action and potency of antibodies generated against a target of interest.
REC name
North West - Preston Research Ethics Committee
REC reference
16/NW/0157
Date of REC Opinion
24 Feb 2016
REC opinion
Favourable Opinion